Harnessing the immune system in glioblastoma
暂无分享,去创建一个
[1] Michael A Vogelbaum,et al. First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. , 2019, Journal of neurosurgery.
[2] K. Ligon,et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 , 2018, Neuro-oncology.
[3] H. Wakimoto,et al. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models , 2018, Clinical Cancer Research.
[4] Dai Fukumura,et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.
[5] Hakho Lee,et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles , 2018, Science Advances.
[6] D. Pardoll,et al. The intestinal microbiome influences checkpoint blockade , 2018, Nature Medicine.
[7] Ken Garber,et al. Driving T-cell immunotherapy to solid tumors , 2018, Nature Biotechnology.
[8] R. Satija,et al. Single-cell RNA sequencing to explore immune cell heterogeneity , 2017, Nature Reviews Immunology.
[9] E. Jaffee,et al. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.
[10] F. Lieberman,et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.
[11] Stephen J. Schuster,et al. Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.
[12] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[13] N. Lemoine,et al. Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent , 2017, Nature Communications.
[14] Act Investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial , 2017 .
[15] F. Macian,et al. Glioblastoma progression is assisted by induction of immunosuppressive function of pericytes through interaction with tumor cells , 2017, Oncotarget.
[16] R. Grossman,et al. HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial , 2017, JAMA oncology.
[17] K. Mansfield,et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.
[18] K. Kerr,et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] B. Nahed,et al. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. , 2017, Journal of neurosurgery.
[20] Jinming Yu,et al. The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis , 2017, Scientific Reports.
[21] Jasmin Herz,et al. Myeloid Cells in the Central Nervous System. , 2017, Immunity.
[22] G. Reifenberger,et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.
[23] M. Lim,et al. Immunotherapy and radiation in glioblastoma , 2017, Journal of Neuro-Oncology.
[24] Andrew J. Park,et al. Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update. , 2017 .
[25] J. Wargo,et al. Hallmarks of response to immune checkpoint blockade , 2017, British Journal of Cancer.
[26] Jedd D. Wolchok,et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.
[27] A. Brandes,et al. OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 , 2017 .
[28] Zhihong Chen,et al. Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. , 2017, Cancer research.
[29] D. Hanahan,et al. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation , 2017, Science Translational Medicine.
[30] D. Quail,et al. The Microenvironmental Landscape of Brain Tumors. , 2017, Cancer cell.
[31] P. Hamilton,et al. Regulatory T cells promote myelin regeneration in the Central Nervous System , 2017, Nature Neuroscience.
[32] W. Lim,et al. The Principles of Engineering Immune Cells to Treat Cancer , 2017, Cell.
[33] G. Mason,et al. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. , 2017, Journal of neurosurgery. Pediatrics.
[34] Mariella G. Filbin,et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq , 2017, Science.
[35] T. Korn,et al. T cell responses in the central nervous system , 2017, Nature Reviews Immunology.
[36] Alberto Mantovani,et al. Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.
[37] Rakesh K. Jain,et al. New Directions in Anti-Angiogenic Therapy for Glioblastoma , 2017, Neurotherapeutics.
[38] Eilon D. Kirson,et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma , 2017 .
[39] L. Recht,et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. , 2017, The Lancet. Oncology.
[40] Xiuli Wang,et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.
[41] R. Fietkau,et al. Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells , 2016, Front. Immunol..
[42] Christopher M. Jackson,et al. Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM , 2016, Science Translational Medicine.
[43] M. Ciesielski,et al. Novel vaccines for glioblastoma: clinical update and perspective. , 2016, Immunotherapy.
[44] A. Faissner,et al. The extracellular matrix niche microenvironment of neural and cancer stem cells in the brain. , 2016, The international journal of biochemistry & cell biology.
[45] K. Tamura,et al. ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM) , 2016 .
[46] D. Merico,et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] R. Stupp,et al. Tumor treating fields: a novel treatment modality and its use in brain tumors , 2016, Neuro-oncology.
[48] M. Weller,et al. Immunological effects of chemotherapy and radiotherapy against brain tumors , 2016, Expert review of anticancer therapy.
[49] Voichita D. Marinescu,et al. Heparanase Promotes Glioma Progression and Is Inversely Correlated with Patient Survival , 2016, Molecular Cancer Research.
[50] Britta Engelhardt,et al. Vascular, glial, and lymphatic immune gateways of the central nervous system , 2016, Acta Neuropathologica.
[51] J. Kochenderfer,et al. Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.
[52] H. Colman,et al. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future , 2016, Current Treatment Options in Oncology.
[53] M. Vetizou,et al. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. , 2016, Immunity.
[54] Renier J. Brentjens,et al. Driving CAR T-cells forward , 2016, Nature Reviews Clinical Oncology.
[55] R. Weissleder,et al. Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. , 2016, Cancer research.
[56] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[57] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[58] V. Chekhonin,et al. Temozolomide promotes genomic and phenotypic changes in glioblastoma cells , 2016, Cancer Cell International.
[59] E. Hattingen,et al. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. , 2016, Journal of the National Cancer Institute.
[60] J. Kuo,et al. CSF1 Overexpression Promotes High-Grade Glioma Formation without Impacting the Polarization Status of Glioma-Associated Microglia and Macrophages. , 2016, Cancer research.
[61] W. Wels,et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival , 2016, Oncoimmunology.
[62] Chih-Hao Chang,et al. Emerging concepts of T cell metabolism as a target of immunotherapy , 2016, Nature Immunology.
[63] J. P. McCoy,et al. Effects of Systemically Administered Hydrocortisone on the Human Immunome , 2016, Scientific Reports.
[64] S. Razavi,et al. Immune Evasion Strategies of Glioblastoma , 2016, Front. Surg..
[65] [World Health Organization classification of tumours of the central nervous system: a summary]. , 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology.
[66] F. Heppner,et al. Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors , 2016, Acta Neuropathologica.
[67] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[68] H. Kaufman,et al. Oncolytic viruses: a new class of immunotherapy drugs , 2015, Nature Reviews Drug Discovery.
[69] D. Hafler,et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma , 2015, Nature Reviews Neurology.
[70] M. Weller,et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. , 2015, Neuro-oncology.
[71] M. Caligiuri,et al. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells , 2015, Scientific Reports.
[72] M. Lim,et al. Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites , 2015, Frontiers in Oncology.
[73] Kevin J. Harrington,et al. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence , 2015, Nature Reviews Cancer.
[74] S. Gautam,et al. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma , 2015, British Journal of Cancer.
[75] Timothy J Keyes,et al. Structural and functional features of central nervous system lymphatics , 2015, Nature.
[76] C. Paulos,et al. Harnessing the Microbiome to Enhance Cancer Immunotherapy , 2015, Journal of immunology research.
[77] Elizabeth A. Repasky,et al. Fever and the thermal regulation of immunity: the immune system feels the heat , 2015, Nature Reviews Immunology.
[78] Maiken Nedergaard,et al. The Glymphatic System: A Beginner’s Guide , 2015, Neurochemical Research.
[79] Gelareh Zadeh,et al. Glioblastoma: pathology, molecular mechanisms and markers , 2015, Acta Neuropathologica.
[80] A. Sloan,et al. Extra-CNS metastasis from glioblastoma: a rare clinical entity , 2015, Expert Review of Anticancer Therapy.
[81] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[82] M. Lesniak,et al. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy , 2015, Oncoimmunology.
[83] C. Sheridan. IDO inhibitors move center stage in immuno-oncology , 2015, Nature Biotechnology.
[84] S. Millis,et al. HER2 expression status in diverse cancers: review of results from 37,992 patients , 2015, Cancer and Metastasis Reviews.
[85] C. Dardis,et al. Immunotherapeutic Advancements for Glioblastoma , 2015, Front. Oncol..
[86] William A. Flavahan,et al. Periostin Secreted by Glioblastoma Stem Cells Recruits M2 Tumor-associated Macrophages and Promotes Malignant Growth , 2014, Nature Cell Biology.
[87] S. H. van der Burg,et al. Therapeutic cancer vaccines. , 2010, The Journal of clinical investigation.
[88] R. Daneman,et al. The blood-brain barrier. , 2015, Cold Spring Harbor perspectives in biology.
[89] David Fortin,et al. Transforming growth factor-beta and its implication in the malignancy of gliomas , 2015, Targeted Oncology.
[90] R. Jain,et al. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.
[91] P. Wen,et al. Immunotherapy advances for glioblastoma. , 2014, Neuro-oncology.
[92] S. Sengupta,et al. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. , 2014, Neuro-oncology.
[93] I. Stratford,et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.
[94] T. Maruyama,et al. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. , 2014, Journal of neurosurgery.
[95] J. Joyce,et al. Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma. , 2014, Immunotherapy.
[96] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[97] R. Kurzrock,et al. HER2 aberrations in cancer: implications for therapy. , 2014, Cancer treatment reviews.
[98] Shawn M. Gillespie,et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.
[99] Alexandre Corthay,et al. Does the Immune System Naturally Protect Against Cancer? , 2014, Front. Immunol..
[100] Katherine K. Matthews,et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. , 2014, Cancer research.
[101] A. D. Van den Abbeele,et al. Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma , 2014, Cancer Immunology Research.
[102] Eduard Batlle,et al. Metastatic stem cells: sources, niches, and vital pathways. , 2014, Cell stem cell.
[103] T. Schwerdtle,et al. Brain capillary pericytes contribute to the immune defense in response to cytokines or LPS in vitro , 2014, Brain Research.
[104] Seth Love,et al. Convection‐Enhanced Drug Delivery to the Brain: Therapeutic Potential and Neuropathological Considerations , 2014, Brain pathology.
[105] K. Hoang-Xuan,et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[106] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[107] Susan M. Chang,et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. , 2014, Neuro-oncology.
[108] P. Coulie,et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.
[109] M. Takeya,et al. Clinical significance of macrophage heterogeneity in human malignant tumors , 2013, Cancer science.
[110] B. Wei,et al. The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression , 2014, Tumor Biology.
[111] Christina S. Leslie,et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.
[112] F. Dammacco,et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. , 2013, Journal of the National Cancer Institute.
[113] S. Ramakrishna,et al. Immune system: a double-edged sword in cancer , 2013, Inflammation Research.
[114] D. Bigner,et al. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. , 2013, Future oncology.
[115] K. Aldape,et al. Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas , 2013, Cancer Immunology Research.
[116] R. Weller,et al. Drainage of Cells and Soluble Antigen from the CNS to Regional Lymph Nodes , 2013, Journal of Neuroimmune Pharmacology.
[117] C. James,et al. Proteoglycans and their roles in brain cancer , 2013, The FEBS journal.
[118] Y. Delneste,et al. Efficiently stimulated adult microglia cross‐prime naive CD8+ T cells injected in the brain , 2013, European journal of immunology.
[119] R. Kaur,et al. Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages , 2013, Clinical Cancer Research.
[120] P. Grandi,et al. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[121] S. Demaria,et al. Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.
[122] C. Schroll,et al. Bystander effects in tumor-free and tumor-bearing rat brains following irradiation by synchrotron X-rays , 2013, International journal of radiation biology.
[123] スティーブン ジェイ. ブレイクモア,,et al. How to treat cancer , 2013 .
[124] A. Sica,et al. Macrophage plasticity and polarization in tissue repair and remodelling , 2013, The Journal of pathology.
[125] W. McBride,et al. Regulatory T Cells in Radiotherapeutic Responses , 2012, Front. Oncol..
[126] C. Chiang,et al. Irradiation Promotes an M2 Macrophage Phenotype in Tumor Hypoxia , 2012, Front. Oncol..
[127] Peng Zhang,et al. Tumor-Associated Microglia/Macrophages Enhance the Invasion of Glioma Stem-like Cells via TGF-β1 Signaling Pathway , 2012, The Journal of Immunology.
[128] Min Li,et al. Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis. , 2012, Cancer letters.
[129] A. N. van den Pol,et al. Oncolytic Virus Therapy for Glioblastoma Multiforme: Concepts and Candidates , 2012, Cancer journal.
[130] M. von Knebel Doeberitz,et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol , 2012, BMC Cancer.
[131] Christopher M. Jackson,et al. Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment , 2011, Clinical & developmental immunology.
[132] K. Margolin,et al. Cytokines in Cancer Immunotherapy , 2011, Cancers.
[133] S. Piantadosi,et al. Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide , 2011, Clinical Cancer Research.
[134] G. Merlino,et al. The Two Faces of Interferon-γ in Cancer , 2011, Clinical Cancer Research.
[135] C. von Kalle,et al. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[136] H. Wishart,et al. Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy , 2011, Journal of immunotherapy.
[137] J. Gui,et al. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. , 2011, Neuro-oncology.
[138] K. Kurisu,et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[139] A. Heimberger,et al. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? , 2011, Neuro-oncology.
[140] R. Juliano,et al. Extracellular Matrix of Glioblastoma Inhibits Polarization and Transmigration of T Cells: The Role of Tenascin-C in Immune Suppression , 2010, The Journal of Immunology.
[141] Markus G. Manz,et al. Development of Monocytes, Macrophages, and Dendritic Cells , 2010, Science.
[142] F. Marincola,et al. Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients , 2010, Clinical Cancer Research.
[143] C. Kim,et al. Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model , 2009, Clinical and Vaccine Immunology.
[144] Pieter Wesseling,et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. , 2009, Neuro-oncology.
[145] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[146] J. Kuratsu,et al. Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas , 2008, The Journal of pathology.
[147] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[148] R. McLendon,et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. , 2008, Neuro-oncology.
[149] Erwin G. Van Meir,et al. Erratum: Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4 (Cancer Research (2007) 67, (6872-6881)) , 2007 .
[150] Erwin G. Van Meir,et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. , 2007, Cancer research.
[151] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[152] C. Chiang,et al. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. , 2007, International journal of radiation oncology, biology, physics.
[153] S. Demaria,et al. Sensors of ionizing radiation effects on the immunological microenvironment of cancer , 2007, International journal of radiation biology.
[154] Mary Helen Barcellos-Hoff,et al. Isoform-Specific Activation of Latent Transforming Growth Factor β (LTGF-β) by Reactive Oxygen Species , 2006, Radiation research.
[155] David J. Yang,et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. , 2006, Neuro-oncology.
[156] K. Camphausen,et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.
[157] F. Pijpers,et al. Therapeutic cancer vaccines , 2005, Nature Reviews Drug Discovery.
[158] V. Kindler,et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion , 2005, Neuroreport.
[159] F. Helmchen,et al. Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo , 2005, Science.
[160] J. Schlom,et al. Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes , 2004, Cancer Research.
[161] K. Iwamoto,et al. A Sense of Danger from Radiation1 , 2004, Radiation research.
[162] C. N. Coleman,et al. Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy , 2003, The Journal of Immunology.
[163] Helga E de Vries,et al. The Blood‐Brain Barrier and Its Role in Immune Privilege in the Central Nervous System , 2003, Journal of neuropathology and experimental neurology.
[164] G. Finocchiaro,et al. Dexamethasone inhibits the anti-tumor effect of interleukin 4 on rat experimental gliomas , 2003, Gene Therapy.
[165] D. Carbone,et al. VEGF as a mediator of tumor-associated immunodeficiency , 2001, Immunologic research.
[166] I. Pastan,et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[167] B. Quesnel,et al. γ‐Ray irradiation induces B7.1 expression in myeloid leukaemic cells , 2000, British journal of haematology.
[168] D. Carbone,et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. , 1998, Journal of immunology.
[169] D. Bigner,et al. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. , 1998, Journal of neurovirology.
[170] D M Coen,et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.